Switzerland has so far been spared tariff threats from the new US President Donald Trump. Nevertheless, Swiss companies are taking precautions.
ARS Pharmaceuticals, Inc.'s stock soared 25% on strong earnings. Learn about neffy's market potential, risks, and future ...
After getting its hands on a massive Quebecois manufacturing plant from Sandoz in 2022, French CDMO Delpharm is making good ...
Amneal Pharmaceuticals, Inc. offers strong growth prospects with undervalued stock, rising revenues, reduced debt, and key ...
Twenty U.S. states including California, Connecticut and Michigan have pushed back against a $10 million settlement that Florida reached with Swiss generic drugmaker Sandoz, saying a key provision ...
After Delpharm bought the Boucherville plant in 2022, Sandoz signed an exclusive partnership with the company to maintain its ...
Sandoz garners chunky demand for 10 year trade â—† Trend continues for issuers to set deal parameters quickly â—† Single digit ...
Skincare product maker Galderma, and pharmaceutical company Sandoz both returned to their home market this week, bringing ...
Four companies have applied to Health Canada to sell copies of Ozempic after its market exclusivity expires on Jan. 4, 2026 ...
TOKYO -- Swiss pharmaceutical company Novartis has pegged its cancer ... Novartis spun off ophthalmology subsidiary Alcon in 2019 and generic drug subsidiary Sandoz in 2023, and announced plans to ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amneal Pharmaceuticals (AMRX – Research Report), Sandoz ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback